Obesity battle heats up again as Novo claws way back into race with Lilly
Novo spent 2025 on the defensive as mounting US pricing pressure and competition led to four guidance cuts and wiped billions from its market value.
Novo spent 2025 on the defensive as mounting US pricing pressure and competition led to four guidance cuts and wiped billions from its market value.